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DOI 10.1016/j.ccr.2011.06.018SUMMARYProinflammatory cytokines are frequently observed in the tumor microenvironment, and chronic inflamma-
tion is involved in cancer initiation and progression. We show that cytokine signaling through the receptor
subunit GP130-IL6ST and the kinase JAK1 generates actomyosin contractility through Rho-kinase depen-
dent signaling. This pathway generates contractile force in stromal fibroblasts to remodel the extracellular
matrix to create tracks for collective migration of squamous carcinoma cells and provides the high levels
of actomyosin contractility required for migration of individual melanoma cells in the rounded, ‘‘amoeboid’’
mode. Thus, cytokine signaling can generate actomyosin contractility in both stroma and tumor cells. Strik-
ingly, actomyosin contractility itself positively modulates activity of the transcription factor STAT3 down-
stream of JAK1, demonstrating positive feedback within the signaling network.INTRODUCTION
Abnormal cell migration and invasion are key components of
metastasis. Tumor cells can move either in a collective fashion
or as individual cells (Friedl and Wolf, 2003a, 2003b, 2010;
Wolf et al., 2003). The contractile force generated by actomyosin
contractility has been shown to play a pivotal role in both collec-
tive and individual migration of tumor cells. Carcinoma-associ-
ated fibroblasts (CAFs) use contractile force and proteolytic
activity to remodel the extracellular matrix to generate tracksSignificance
Actomyosin contractility plays a key role in migration of tumor
the extracellular matrix by tumor fibroblasts to permit cell migra
and JAK1 stimulates actomyosin contractility in tumor cells an
signaling through this axis may be effective to block differentfor migration of cancer cells as collective strands led by a fibro-
blast (Gaggioli et al., 2007). Force-mediated matrix remodelling
by CAFs depends on actomyosin contractility generated through
Rho-Rho-kinase (ROCK) signaling (Gaggioli et al., 2007; Hooper
et al., 2010). ROCK phosphorylates MYPT1, the targeting
subunit of myosin phosphatase, resulting in decreased myosin
phosphatase activity and thereby increased phosphorylation of
the regulatory myosin light-chain 2 (MLC2) and activity of myosin
II (Ito et al., 2004). High levels of Rho-ROCK signaling in tumor
cells drive high levels of actomyosin contractility and arecells, both in the tumor cells themselves and in remodelling
tion. We show that cytokine signaling through GP130-IL6ST
d in stroma. These results suggest that strategies to inhibit
modes of tumor cell invasion.
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Figure 1. Janus Kinase Activity Is Required for CAF-Induced Matrix Remodelling and SCC12 Collective Invasion
(A) Matrix contraction by CAFs treated with: P6 (pan-JAK); JAK2 inhibitors II, III, and AG490 mcf; JAK3 inhibitors II, IV, and VI; and ROCK inhibitor Y27632.
*p < 0.01.
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JAK Signaling to Actomyosin Contractilityassociated with movement of individual cells in a rounded or
‘‘amoeboid’’ fashion; lower levels of contractility are associated
with Rac-dependent elongated movement (Sahai and Marshall,
2003; Sanz-Moreno et al., 2008; Wilkinson et al., 2005; Wyckoff
et al., 2006). The rounded, ’’amoeboid’’ form of movement
occurs where the composition of the extracellular matrix allows
the contractile force of the cell to deform the matrix (Friedl and
Wolf, 2003a; Wyckoff et al., 2006). High actomyosin contractility
may also provide cells with mechanical strength to resist shear
forces following entry into the blood supply (Pinner and Sahai,
2008; Sanz-Moreno et al., 2008).
The signaling mechanisms generating contractile force in
CAFs and tumor cells are not fully understood. It is unclear
whether extracellular signals from growth factors or cytokines
play a role and if they do what signaling pathways are engaged.
In CAF-dependent ECM remodeling, it was recently shown that
a kinase inhibitor, Pyridone 6 (P6) (Thompson et al., 2002),
prevents CAF-dependent matrix remodeling (Hooper et al.,
2010). P6 is an inhibitor of the JAK family kinases, JAK1, JAK2,
JAK3, and TYK2, which are activated by cytokine-signaling
pathways (Liu et al., 1997). This observation suggests that
cytokine signaling may be involved in the generation of actomy-
osin contractility of CAFs. CAFs secrete a broad range of
growth factors and cytokines (Kalluri and Zeisberg, 2006).
Abnormal cytokine signaling is thought to play key roles in
cancer because many studies have demonstrated a strong
association between chronic inflammation and cancer (Aggar-
wal et al., 2009; Bromberg and Wang, 2009; Greten et al.,
2004; Grivennikov and Karin, 2010). Cancer cells also produce
cytokines that attract inflammatory cells, which also express
a wide array of cytokines, proteases, and proinvasive extracel-
lular matrix proteins (Coussens and Werb, 2002). Proinflamma-
tory cytokines such as those of the interleukin-6 (IL-6) family
(Erez et al., 2010; Kim et al., 2009; Melnikova and Bar-Eli,
2009; Rose-John et al., 2007) are frequently observed in the
tumor microenvironment. IL-6 is a key driver in a mouse model
of inflammation-associated colorectal cancer (Bollrath et al.,
2009; Grivennikov et al., 2009) and provides an attractant for
recruitment of circulating tumor cells (Kim et al., 2009). Cytokine
signaling activates JAK family protein kinases resulting in tyro-
sine phosphorylation of substrates including the STAT (signal
transducers and activators of transcription) family of transcrip-
tion factors leading to the induction of gene expression
(Pedranzini et al., 2004; Yu et al., 2009). STAT3 is constitutively
activated in a variety of human malignancies, including prostate,
lung, brain, breast, melanoma, and squamous cell carcinomas
(Catlett-Falcone et al., 1999; Pedranzini et al., 2004), and is
thought to be a key mediator of oncogenesis (Bromberg et al.,
1999; Yu et al., 2009).(B) Invasion of SCC12 cells after treatment with P6, (i) coculture of CAFs and SCC
cells, and (iii) acellular matrix from untreated CAFs, overlaid with SCC12 cells an
(C) Matrix contraction after siRNA depletion of JAK1 (n = 3, mean + SD; *p < 0.0
(D) Quantitation of organotypic invasion assays (n = 3, mean + SD; *p < 0.01). Bo
(E) Representative images of organotypic invasion assay. Scale bar, 100 mm.
(F) Immunoblot for P-MLC after treatment with P6.
(G) Immunoblot for P-STAT3 and P-MLC.
(H) Immunoblot for JAK1, P-STAT3, P-MLC, and MLC expression after transfect
See also Figure S1.In the studies described here, we investigate whether cytokine
signaling through JAK kinases is involved in generating actomy-
osin contractility in CAFs and melanoma cells.
RESULTS
JAK1 Regulates Actomyosin Contractility in CAFs
and in Rounded Cell Movement
CAF-dependent matrix remodelling is essential for collective
carcinoma cell invasion (Gaggioli et al., 2007). Screening for
compounds that inhibit CAF-induced contraction of collagen
lattices suggests a role for JAK signaling in matrix remodelling
because the single JAK kinase inhibitor P6 tested blocked
remodelling (Hooper et al., 2010). P6 inhibits multiple members
of the JAK family (Pedranzini et al., 2006), so we used JAK
isoform-specific inhibitors to probe which JAKs are involved;
neither JAK2 nor JAK3-specific inhibitors recapitulated the effect
of the pan-JAK inhibitor (P6) on matrix remodelling (Figure 1A),
suggesting that JAKI is the family member involved.
To extend these results, we used an organotypic assay
utilizing a squamous cell carcinoma cell line (SCC12) and CAFs
(Gaggioli et al., 2007; Hooper et al., 2010). Figure 1B (panel i)
shows that P6 dramatically blocked SCC invasion. In this assay
it is possible to allow the CAFs to remodel the matrix before
killing them and then adding tumor cells to the assay (Gaggioli
et al., 2007). If CAFs were treated with P6 during matrix remod-
elling, SCC12 invasion was blocked (Figure 1Bii). However if
untreated CAFs were allowed to remodel the matrix, killed, and
then SCC12 cells added in the presence of P6, invasion was
unaffected (Figure 1Biii). Thus, the effects of inhibiting JAK on
collective invasion are on CAFs, not tumor cells. Treatment of
CAFs with the JAK2-specific inhibitor SD1029 did not affect
invasion (see Figure S1A available online). To confirm these
results, we used RNA interference to abrogate expression of
individual JAKs in CAFs. Figures 1C–1E and Figure S1B show
that the RNAi-mediated knockdown of JAK1 dramatically
reduced the capacity of CAFs to contract collagen lattices and
induce SCC invasion. RNAi against JAK2 and TYK2 had no effect
in these assays (Figure S1B; data not shown). Figures S1C–S1G
show that treatment with P6 had no effect on viability, adhesion,
MMP secretion, or the migration and invasion of CAFs into a
3D matrix. These results suggest that the effects of P6 on
matrix remodelling are a consequence of inhibiting actomyosin
contractility. Actomyosin contractility in CAFs, as in many other
cell types, results from phosphorylation of MLC2 in myosin II
downstream of the Rho kinases ROCK I and II (Gaggioli et al.,
2007). To determine if JAKs regulate actomyosin contractility,
we investigated phosphorylation of MLC2 following P6 treat-
ment. Figure 1F shows that P6 reduces MLC2 phosphorylation12 cells, (ii) acellular matrix from CAFs treated with P6 and overlaid with SCC12
d treated with P6. *p < 0.01.
1). Bottom panel shows immunoblot for JAK1.
ttom panel shows immunoblot for JAK1.
ion with siRNAs against JAK1 or P6 treatment for 96 hr.
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JAK Signaling to Actomyosin Contractility(P-MLC), whereas a specific JAK2 inhibitor had no effect (Fig-
ure S1H), suggesting that the JAK1 signals to MLC2 phosphory-
lation. Similarly, abrogating JAK1 expression with four different
siRNAs reduced MLC2 phosphorylation (Figure 1G). Depletion
of JAK1 by siRNA reduced total MLC2 levels; this appears to
be a consequence of long-term abrogation of JAK1 signaling in
CAFs because prolonged treatment with P6 also reduced total
MLC2 levels (Figure 1H).
In movement of individual tumor cells rounded, ‘‘amoeboid’’
modes of movement are associated with high levels of
actomyosin contractility (Wilkinson et al., 2005). A375M2 mela-
noma cells have high levels of MLC2 phosphorylation, a round,
contractile morphology, and move in a rounded, ’’amoeboid’’
manner on top of or through deformable collagen matrices
(Sanz-Moreno et al., 2008). Partial inhibition of actomyosin
contractility results in elongated morphology and migration in a
Rac-dependent protrusive manner (Sanz-Moreno et al., 2008).
MLC2 phosphorylation in A375M2 cells was decreased following
treatment with P6 (Figure 2A; Figure S2A) or depletion of JAK1 by
siRNA (Figure 2B). The reduction in actomyosin contractility
following P6 treatment or siRNA-mediated knockdown of JAK1
led to an elongated morphology (Figures 2C and 2D) similar to
the effects of ROCK inhibition (Sanz-Moreno et al., 2008). Similar
to CAFs, blocking JAK1 signaling in A375M2melanoma cells had
no effect on cell viability or adhesion (Figures S2B and S2C).
Consistent with the effects on contractility, the proportion of cells
with a round, contractile morphology was reduced, and elon-
gated cells increased following treatment with P6 (Figure 2C) or
by siRNA-mediated knockdown of JAK1 (Figures 2D and 2E).
These elongated cells continued to move (Figure S2D). No
increase in cell elongation was seen following targeting other
members of the JAK family by siRNA (Figure S2E) or with
a JAK2 inhibitor (data not shown). Thus, in both CAFs and mela-
noma cells, JAK1 signaling regulates actomyosin contractility by
controlling the levels of phosphorylated-MLC2. On a rigid
substrate where cells have an elongated shape, abrogation of
JAK signaling led to increased membrane ruffles and cell flat-
tening but no obvious effect on cell elongation (Figure S2F).
JAK inhibition potentiated blockade of MLC2 phosphorylation by
submaximal doses of ROCK inhibitor, consistent with JAK1 and
ROCK operating in the same signaling pathway (data not shown)
GP130-IL6ST Regulates Actomyosin Contractility
in CAFs and Tumor Cells
JAK1 can be activated by a variety of transmembrane receptors
including cytokine receptors involved in inflammatory responses
(O’Shea et al., 2002; Yamaoka et al., 2004). GP130-IL6ST is the
common subunit for a number of cytokine receptors, and its
expression has been correlated with matrix remodelling during
neoangiogenesis (Salguero et al., 2009). We investigated the
role of GP130-IL6ST in CAF-induced matrix contraction, SCC
invasion, and rounded, ‘‘amoeboid’’ movement of tumor cells.
Depletion of GP130-IL6ST in CAFs using siRNAs resulted in
reduction of matrix contraction (Figure 3A), MLC2 phosphoryla-
tion (Figure S3A), and SCC12 invasion (Figures 3B and 3C). Thus,
GP130-IL6ST signaling to JAK1 drives actomyosin contractility
in CAFs and mediates matrix remodelling.
To investigate whether JAK1 signaling to MLC2 phosphoryla-
tion involves GP130-IL6ST in tumor cells, we depleted A375M2232 Cancer Cell 20, 229–245, August 16, 2011 ª2011 Elsevier Inc.cells of GP130-IL6ST by RNA interference. Depletion of
GP130-IL6ST resulted in reduced MLC2 phosphorylation (Fig-
ures 3D and 3E). GP130-IL6ST depleted A375M2 cells invaded
into a 3D collagen I matrix as elongated rather than round cells
(Figures 3F and 3G) and had reduced invasive capacity (Fig-
ure S3B). Consistent with these changes in morphology of
invaded cells, depletion of GP130-IL6ST by RNA interference
resulted in reduction in the proportion of A375M2 cells on top
of a collagen I matrix with a round, contractile morphology
(Figures S3C and S3D and Movie S1). To extend these observa-
tions, we overexpressed GP130-IL6ST in SKMEL28 melanoma
cells that have an elongated morphology and mode of invasion
to see if overexpression would promote MLC2 phosphorylation
and a round morphology. Overexpression of GP130-IL6ST
resulted in an increased proportion of cells with a round,
contractile morphology (Figures S3E and S3F). The increased
proportion of cells with a round morphology resulting from over-
expression of GP130 was blocked by P6 (Figure S3F). Interest-
ingly, even in A375M2 cells where over 90% of cells have a
round, contractile morphology, overexpression of GP130-IL6ST
increased the proportion of round cells (data not shown). Over-
expression of GP130-IL6ST led to increased MLC2 phosphory-
lation (Figures S3E and S3G) that was dependent on ROCK
because it was blocked by the ROCK inhibitor H1152 (Fig-
ure S3G). Furthermore, overexpression of GP130-IL6ST led to
a significant increase in invasion of SKMEL28 and A375M2 cells
into a collagen I matrix (Figure S3H; data not shown).
To extend these results to migration of tumor cells in vivo, we
used two-photon intravital imaging to examine the movement of
cells in A375M2 xenografts. Imaging of two stable cell lines
where GP130-IL6ST was depleted by expression of different
shRNAs showed that tumor cell motility was significantly
reduced compared to cells containing a control shRNA vector
(Movie S2 and Movie S3). Figure 3H shows merged red, green,
and blue images taken from three different time points 630 s
apart in the time-lapse movies; spatial separation of colors indi-
catesmovement, whereas cells that do not migrate appear white
(Pinner et al., 2009). Previous work has shown that in A375M2
tumors, cell movement at the periphery is predominantly
rounded, ‘‘amoeboid’’ movement (Pinner and Sahai, 2008;
Sanz-Moreno et al., 2008). Importantly, the reduction in motility
of GP130-IL6ST depleted cells correlated with reduced levels
of rounded, ‘‘amoeboid’’ movement (Figure 3I; Figure S3I). These
data strongly support the argument that signaling through
GP130-IL6ST and the JAK pathway drives rounded, ‘‘amoeboid’’
movement in culture and in vivo.
Cytokines of the IL-6 Family Regulate Actomyosin
Contractility
The cytokine oncostatin M (OSM) signals through GP130-IL6ST
and is a member of the IL-6 family. Because OSM signaling has
been linked to adverse clinical outcome in squamous cell carci-
noma (Ng et al., 2007), we investigated the role of OSM in matrix
remodelling. Figures 4A and 4B show that stimulation of CAFs by
OSM increased contraction of collagen lattices, whereas Fig-
ure 4C shows that OSM increased SCC12 cell invasion in the
organotypic assay. These effects of OSM are mediated by JAK1
because they are eliminated by treatment with P6 or JAK1
siRNA, but not by JAK2 inhibitor SD1029 (Figures 4A–4C).
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Figure 2. Jak Regulates Actomyosin Contractility in Amoeboid Cell Movement of Melanoma Cells
(A) Immunoblot of P-MLC in A375M2 cells on a thick layer of collagen and treated with P6.
(B) Upper panel shows immunoblot of P-MLC after depletion of JAK1, arrow shows position of JAK1, and lower panel quantification (n = 4, error bars are +SE;
**p < 0.01 and *p < 0.05).
(C) Images of A375M2 cells plated on a thick layer of collagen for 24 hr and treated with P6. Scale bar represents 50 mm.
(D) Images of A375M2 cells after JAK1 depletion. Scale bar represents 50 mm.
(E) Percent (%) rounded and elongated cells after siRNA depletion of JAK1 (600 cells/experiment; n = 3, error bars are +SE). *p < 0.05; ***p < 0.005.
See also Figure S2.
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JAK Signaling to Actomyosin ContractilityBoth basal and OSM stimulation of MLC2 phosphorylation are
dependent on JAK1 signaling (Figures 4D and 4E) and ROCK (Fig-
ure 4D). Thus, OSM signaling through GP130-IL6ST, JAK1, and
ROCK drives actomyosin contractility and matrix remodelling by
CAFs for collective invasion of squamous cell carcinoma cells.
Interestingly, P6 treatment also blocked basal gel contraction by
CAFs (Figures 1A and 4A) and invasion bySCC12cells (Figures 1B
and 4C), indicating that under the conditions of these assays, in
which complete media are used, the basal level of actomyosin
contractility is mediated by JAK1 signaling (Figures 4D and 4E).
Inmelanoma, expression of IL-6 has been correlated with poor
prognosis (Melnikova and Bar-Eli, 2009); therefore, we assessed
if treatment of melanoma cells with IL-6 would affect cell
morphology and mode of cell migration. We chose WM1361
cells where approximately 25%of cells invade into a 3D collagen
I matrix with an elongated morphology and investigated
whether IL-6 treatment would increase the proportion of cells
invading in a rounded, ‘‘amoeboid’’ manner. IL-6 treatment led
to an increase in the proportion of round cells and a 2-fold
increase in invasion (Figures 4F and 4G). Treatment of three
other melanoma cell lines, A375M2, WM1366, and SKMEL28,
with IL-6 or leukemia inhibitory factor (LIF), which also signals
through GP130-IL6ST (Gearing et al., 1992), resulted in in-
creased invasion (Figures S4A and S4B). A375P and A375M2
cells plated on top of a collagen matrix and treated with IL-6 dis-
played an increase in the proportion of cells with a round,
contractile morphology (Figures S4C and S4D). However, IL-6
stimulation, unlike OSM, had no effect on CAF-dependent gel
contraction (Figure S4E) and STAT3 phosphorylation (Fig-
ure S4F), whereas it induced phosphorylation of STAT3 in
SCC12 cells (Figure S4F). The absence of an IL-6 dependent
response in CAFs compared to SCC12 cells may be explained
by the low expression level of the IL-6 specific coreceptor
GP80 in CAFs (Figure S4G).
Interplay between Actomyosin Contractility
and JAK1-STAT3 Regulated Transcription
Key outputs of JAK signaling are tyrosine phosphorylation and
activation of the STAT family of transcription factors (Bromberg
et al., 1999; Yu et al., 2009). In the course of these experiments,
we noted that treatment with ROCK inhibitors reduced phos-
phorylation of STAT3 both in CAFs (Figure 5A) and A375M2 cells
(Figure 5B; Figure S5A). Therefore, we investigated whether acti-
vation of ROCK signaling leads to STAT3 phosphorylation. We
used A375P cells expressing a ROCK-estrogen receptor fusion
protein (ROCKER) to provide tamoxifen-inducible ROCK activity
(Croft and Olson, 2006). Induction of ROCK activity resulted in
STAT3 phosphorylation soon after tamoxifen treatment (Fig-(C) Invasion index of SCC12 cells from assays as in (B) (n = 3, mean + SD; *p < 0
(D) Immunoblots of P-MLC in A375M2 cells on thick collagen after siRNA deplet
(E) Quantification of P-MLC levels (n = 3, error bars are +SE; *p < 0.05).
(F) Images of GFP-A375M2 cells stably transfected with shRNAs after 24 hr of in
(G) Percent (%) rounded or elongated cells (n = 3, mean + SE; **p < 0.01).
(H) Multiphoton intravital microscopy of A375M2 subcutaneous tumors, and rep
panels). Left-hand panels illustrate melanoma cells in green, collagen fibers in
magnification motion analysis of areas indicated in yellow; red, green, and blue im
indicate motile cells.
(I) Quantification of the number of motile cells in control and two different pools
See also Figure S3.ure S5B) in a time frame similar to that for increasedMLC2 phos-
phorylation. Induction of STAT3 phosphorylation by ROCK
required kinase activity because a kinase-inactive version of
ROCKER did not lead to inducible STAT3 phosphorylation
(Figure S5B). STAT3 phosphorylation was inhibited by JAK inhib-
itor P6, showing that ROCK-induced STAT3 phosphorylation
required JAK kinase activity (Figure S5C).
Accordingly, we assessed the role of STAT3 in CAF matrix re-
modeling and SCC12 cell invasion. In CAFs, STAT3 expression
silencing using specific siRNA resulted in decreased matrix
contraction (Figure 5C) and SCC12 cell invasion (Figures 5D
and 5E). Figure 5F shows that, similar to JAK1 knockdown,
STAT3 silencing in CAFs reduces the levels of phosphorylated
and total MLC2 protein. The level of GP130-IL6ST protein ex-
pression was also decreased (Figure 5F), which suggests a
possible positive regulatory loop via STAT3.
To investigate whether STAT factor signaling impacts on
actomyosin contractility in A375M2 melanoma cells, we used
as a readout of actomyosin contractility effects on the round,
contractile cell morphology on top of a thick layer of collagen I.
A375M2 cells were transfected with siRNAs targeting STAT1,
STAT2, STAT3, STAT5A, or STAT5B; knockdown of STAT3
expression decreased the proportion of cells with round,
contractile morphology (Figures 5G and 5H; Figure S5D). Deple-
tion of STAT3 resulted in diminished levels of MLC2 phosphory-
lation (Figures 5I and 5J).
To examine if there are links among ROCK activity,
actomyosin contractility, and STAT3-mediated transcriptional
responses, we performed gene expression analysis. A375M2
cells were plated on top of a thick layer of collagen I and treated
with ROCK inhibitors to reduce MLC2 phosphorylation or
blebbistatin to directly inhibit Myosin II (Straight et al., 2003).
To generate conditions of high actomyosin contractility, we
plated cells on a thin layer of collagen I, where MLC2 phosphor-
ylation is very high (Figure S6). In this gene expression analysis,
we included A375P cells that have lower levels of MLC2
phosphorylation than A375M2 and have a predominantly elon-
gated phenotype when plated on collagen (Sanz-Moreno et al.,
2008). Genes upregulated in conditions of high contractility
and downregulated in all treatments that decreased contractility
are shown in Figure 6A. GeneGo Network Enrichment analysis
(http://www.genego.com/metacore.php) showed that one of
the main transcriptional networks in this data set is centered
on the STAT family of transcription factors (Figure 6B) and
includes genes such asGP130-IL6ST, the IL-6 receptor a subunit
(IL6R), the cytokine LIF, and the LIF receptor a (LIFR). In confir-
mation of the gene expression data, in A375M2 cells treated
with Y27632, H1152, blebbistatin, or in A375P cells, the protein.01). Bottom panel shows immunoblot for GP130-IL6ST.
ion of GP130-IL6ST.
vasion into collagen I. Scale bar represents 50 mm.
resentative images of control (upper panels) and GP130-IL6ST shRNA (lower
red, and reflective material in blue. Middle and right panels show at higher
ages from three time points 630 s apart are overlaid, and distinct areas of color
of GP130-IL6ST shRNA cells. ns, not significant.
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Figure 4. Cytokines of the IL-6 Family Regulate Actomyosin Contractility
(A) Matrix contraction by CAFs after exposure to 2 ng/ml OSM ± P6 (n = 3, mean + SD; *p < 0.01). Lower panel is representative image of contracted gels.
(B) Matrix contraction by CAFs after depletion of JAK1, ±2 ng/ml OSM (n = 3, mean + SD; *p < 0.01).
(C) SCC12 invasion after treatment with 2 ng/ml OSM ± P6 (n = 3, mean + SD; *p < 0.05 and **p < 0.01).
(D) Quantification of P-MLC levels in CAFs following 30 min treatment with 2 ng/ml OSM ± P6, Y27632, or H1152 treatment. Mean of five independent
experiments +SD (*p < 0.05 and **p < 0.01). ns, not significant.
(E) Immunoblot of P-MLC from CAFs following 30 min treatment with 2 ng/ml OSM ± siRNAs against JAK1.
(F) Invasion index of WM1361 cells treated with IL-6 (n = 4; mean + SE; *p < 0.05).
(G) Box and whisker plot of morphology of GFP-WM1361 cells invading into collagen in the presence of 30 ng/ml IL-6 expressed as percent (%) rounded cells (n =
4; *p < 0.05).
See also Figure S4.
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JAK Signaling to Actomyosin Contractilitylevels of secreted LIF and GP130-IL6ST were lower than in
control cells (Figures 7A and 7B). Furthermore, ablation of JAK
signaling also decreased expression of LIF and GP130-IL6ST
(Figures S7A and S7B). To establish the role of some of these236 Cancer Cell 20, 229–245, August 16, 2011 ª2011 Elsevier Inc.target genes, we used siRNA to silence expression of LIF,
LIFR, and IL-6R; this resulted in a significant decrease in the
levels of P-MLC (Figures 7C–7F). In accordance with these
observations, the proportion of cells with a round, contractile
Cancer Cell
JAK Signaling to Actomyosin Contractilityphenotype was also reduced (Figures 7G–7L). These results
show that multiple components of the cytokine-signaling
network like JAK1, GP130-IL6ST, and STAT3 are required to
generate a highly contractile phenotype in A375M2 cells and
that expression of some of these genes are regulated by
ROCK and actomyosin contractility, providing evidence for posi-
tive feedback in the network.
It has been previously shown that GP130-IL6ST-JAK-STAT
signaling establishes a positive feedback loop that impinges on
the transcriptional regulation of components of the signaling
network, and this is the basis for activation in tumors (Yu et al.,
2009). STAT3 regulates its own expression (Snyder et al.,
2008) and that of GP130-IL6ST (O’Brien and Manolagas,
1997). Consistent with these findings, JAK inhibitor treatment
of A375M2 cells resulted in a significant decrease of GP130-
IL6ST levels (Figure S7B) and STAT3 levels (Figure S7C). Like-
wise, activation of the GP130/IL6ST-JAK signaling through IL-6
stimulation resulted in an increase of STAT3 protein levels (Fig-
ure S7D) in A375M2 cells.
These results show that signaling through GP130-IL6ST,
JAK, and STAT increases actomyosin contractility, and ROCK
signaling to actomyosin contractility increases STAT3 phosphor-
ylation and transcriptional responses. Thus, STAT3 signaling and
actomyosin contractility are interdependent and cross-regulate
each other (Figure S7E).
STAT3 Phosphorylation in Melanoma Correlates
with Round Cell Morphology In Vivo
To examine if activation of the JAK1-STAT3 signaling pathway is
correlated with a more contractile phenotype in melanomas
in vivo, we first analyzed tumor xenografts of A375M2 and
WM1361 melanoma cells in nude mice. Tumor sections were
stained for phosphorylated STAT3 (P-STAT3) as amarker of acti-
vated JAK1-STAT3 signaling; cell morphology was assessed by
dividing the shortest diameter of each cell by the longest one
(ratio-b/ratio-a) to produce a score between 0 and 1, with
perfectly round cells having a score of 1. Previous studies have
shown that this is a valid approach for assessing themorphology
of tumor cells in melanomas (Viros et al., 2008). Tumors from
A375M2 cells had an average roundness score of 0.764 (SD =
0.17; p < 0.0001) compared to 0.52 (SD = 0.13; p < 0.0001) for
WM1361 (Figure S8A). Figure S8B shows that A375M2 tumors
compared to WM1361 tumors have a much higher percentage
of tumor cells staining positive for P-STAT3 (p = 0.000492).
Furthermore, the intensity of P-STAT3 staining was higher in
A375M2 tumor sections than in WM1361 (Figures 8A and 8B).
To further correlate staining with cell morphology, we assigned
scores for P-STAT3 staining ranging from 0 (negative staining),
1–2 (moderate staining), and to 3 (intense staining). The cells
with the highest degree of roundness in A375M2 tumors dis-
played the most intense staining (Figure 8A). Interestingly, even
though WM1361 xenografts showed less overall staining for
P-STAT3, we still observed a strong correlation between
intensity of P-STAT3 staining and roundness (Figure 8B). We
determined the role of GP130-IL6ST signaling in regulating
morphology and degree of STAT3 phosphorylation in A375M2
cells in vivo. Analysis of the shape of cells in tumors derived
from stable cell lines where GP130-IL6ST was depleted by
expression of shRNA showed that they were more elongatedthan controls (Figure S8C). Furthermore, GP130-IL6ST depleted
cells showed significantly less P-STAT3 staining than the
controls, showing once more that STAT3 phosphorylation corre-
lates with roundness (Figure S8C).
To extend these studies from subcutaneous xenografts to
the clinical setting, we collected primary melanomas from 85
patients (Table S1). Because these studies involved a much
larger series of samples, we estimated cell shape across whole
tumor sections by obtaining a cell shape score in which we
counted the percentage of cells in 4 categories ranging from
0 to 4 of increasing elongation (Experimental Procedures). This
semiquantitative assessment has been shown to agree with
the quantitative measurements of cell shape used in Figures
8A and 8B (Viros et al., 2008). Figures 8C and 8D show that the
dermal invasive front of the majority of tumors consists of cells
with a rounded morphology. Round cells predominated in the
invasive front even when the cells in the body of the tumor had
an elongated morphology (Figures 8C and 8D). These patholog-
ical findings closely mirror our imaging of A375M2 xenografts
where the cells at the edge of the tumor abutting the interstitial
matrix have a round morphology, and the cells in the body of
the tumor are elongated (Figure 3H; Movie S2) (Sanz-Moreno
et al., 2008). In no case did we find elongated cells in the invasive
front when the tumor body consisted of primarily round cells.
In accordance with our experimental findings that phosphoryla-
tion of STAT3 is associated with a round morphology and amoe-
boid-type movement, we found that there was a correlation
between more intense P-STAT3 staining and round morphology
in a set of 19 primary melanomas (Figure 8E). In many cases we
could observe a gradient of P-STAT3 intensity toward the inva-
sive front of primary tumors (Figure 8F). In tumors in which the
body as well as the invasive front is composed of rounded cells,
P-STAT3 was found throughout the tumor (Figure S8D).
Analysis of cell morphology from a subset of primary tumors
for which we had metastases (n = 16) showed that metastases
were often composed of more homogeneous round cell popula-
tions (Figure S8E). We examined cell morphology and P-STAT3
in metastases from three patients with melanoma (Table S2
shows clinical characteristics). In patient A the metastasis
displayed a very elongated morphology with little staining for
P-STAT3 (Figure S8F), whereas in patient B the cells had
a predominantly round morphology and positive staining for
P-STAT3 (Figure S8F and quantification in Figure S8G). We
also examined two separate metastases from patient C that
were surgically resected within a 3 year interval. Figure S8F
shows that metastasis C1 showed cells with a predominantly
elongated morphology and little staining for P-STAT3, whereas
in metastasis C2 the cells were predominantly round and had
higher staining for P-STAT3.
These observations show that in human melanoma samples
as in cultured cells, activation of the JAK pathway is correlated
with round cell morphology.
DISCUSSION
During tumor development, formation of abnormal microenvi-
ronment plays a crucial role in tumor cell proliferation, survival,
and invasion (De Wever and Mareel, 2003). Both tumor and
stromal cells contribute to formation of the microenvironmentCancer Cell 20, 229–245, August 16, 2011 ª2011 Elsevier Inc. 237
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Figure 5. Rho Kinase Promotes STAT3 Phosphorylation
(A) Immunoblot of P-STAT3 and P-MLC in CAFs after treatment with H1152. (B) is as (A) for A375M2 cells after treatment with H1152.
(C) Matrix contraction after 4 day depletion of STAT3 in CAFs (n = 3, mean + SD; *p < 0.01).
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Figure 6. Rho Kinase and Actomyosin
Contractility Promote STAT3-Dependent
Transcriptional Responses
(A) Heat map of gene expression following inhibi-
tion of actomyosin contractility in A375M2 cells.
Numbers at top indicate experimental condition.
Genes upregulated in conditions of high contrac-
tility and downregulated in all treatments that
decreased contractility are shown; blue indicates
underexpression, red overexpression, and inten-
sity of color indicates relative change. Red arrows
point to GP130-IL6ST and LIF.
(B) Cytokine network following network enrich-
ment analysis using MetaCore from GeneGo Inc.
(http://www.genego.com/metacore.php). Down-
regulated genes are marked with blue circles
comparing treatments and A375M2 cells on
a thick layer of collagen I.
See also Figure S6.
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JAK Signaling to Actomyosin Contractility(Coussens andWerb, 2002; Erez et al., 2010). Remodelling of the
extracellular matrix involves metalloproteinases, integrins, and
force generation by actomyosin contractility in stromal and
tumor cells (Grinnell, 2003; Meshel et al., 2005) (Gaggioli et al.,(D) SCC12 invasion assay after 7 day exposure of CAFs depleted for STAT3 (n = 3, mean + SD; *p < 0.01).
(E) Representative images of organotypic invasion assays with STAT3-depleted CAFs. Scale bar represents
(F) Immunoblot for P-MLC and GP130-IL6ST in STAT3-depleted CAFs.
(G) Images of A375M2 cells on thick collagen after siRNA depletion of STAT3. Scale bar represents 50 mm
(H) Percent (%) rounded and elongated cells in STAT3-depleted A375M2; 600 cells/experiment (n = 3, mean
(I) Immunoblot of P-MLC in STAT3-depleted A375M2.
(J) Quantification of P-MLC levels compared to STAT3 expression levels (n = 3, error bars are +SE; *p < 0.0
See also Figure S5.
Cancer Cell 20, 229–2452007) (Provenzano et al., 2006). Actomy-
osin contractility is also required to
provide contractile force for tumor cell
movement (Gaggioli et al., 2007) with
high levels of actomyosin contractility
driving rounded, ‘‘amoeboid’’ forms of
individual cell movement (Sanz-Moreno
et al., 2008). Strikingly, we find that the
invasive fronts of melanomas mainly
consist of rounded cells even though the
body of the tumor may be made up of
elongated cells (Figures 8C and 8D),
arguing that melanoma cells at the inva-
sive front are using the rounded, ‘‘amoe-
boid’’ form of cell movement.
Cytokine production is a key feature
of the tumor microenvironment (Brom-
berg and Wang, 2009; Coussens and
Werb, 2002; Erez et al., 2010); we show
a role for cytokine signaling through
GP130-IL6ST/JAK1 to regulate ROCK-
dependent actomyosin contractility. This
pathway drives matrix remodeling by
CAFs and the rounded, ‘‘amoeboid’’
mode of migration of melanoma cells.
Rounded melanoma cells stain stronglyfor P-STAT3, indicating activation of the JAK signaling pathway
(Figure 8F). We show that multiple components of the cytokine
network (Figure 6B) contribute to signaling to actomyosin
contractility because silencing expression of GP130-IL6ST,50 mm.
+ SE). *p < 0.05; **p < 0.01.
5) from (I).
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Cancer Cell
JAK Signaling to Actomyosin ContractilityJAK1, the cytokine LIF, its specific receptor LIFR, and the
specific IL-6 receptor IL-6R (GP80) all reduce actomyosin
contractility in melanoma cells (Figure 7). In CAFs we show
that the cytokine OSM signaling through GP130-IL6ST stimu-
lates actomyosin contractility. Interestingly, OSM is known to
induce lung and liver fibrosis (Mozaffarian et al., 2008), and
epithelial-mesenchymal transition to a myofibroblastic pheno-
type (Nightingale et al., 2004), predisposing factors to cancer
(Radisky et al., 2007). Unlike melanoma cells where the
GP130-IL6ST/JAK1-ROCK signaling is required for tumor cell
movement, in collective invasion of squamous cell carcinoma
cells, this pathway is not required in the tumor cells but is
required in CAFs to remodel the matrix.
A link between JAK signaling and actomyosin contractility has
recently been demonstrated in vascular smooth muscle cells
where angiotensin II, acting through the G protein-coupled AT1
receptor, activates JAK2 that phosphorylates a Rho guanine
nucleotide exchange factor, ARHGEF1, to activate RhoA to the
GTP-bound state. This leads to activation of ROCK and conse-
quent phosphorylation of MLC2 (Guilluy et al., 2010). In CAFs
and melanoma cells, signaling through JAK1 may involve some
of the same elements as in vascular smooth muscle cells
becausewe have found that basal RhoA activity in CAFs is sensi-
tive to inhibition of JAK (Figure S7F), and OSM stimulates RhoA
activation in a JAK-dependent manner (Figure S7G). Importantly,
we show that in melanomas in vivo, the round, contractile
morphology associated with high actomyosin contractility is
associated with P-STAT3 (Figure 8; Figure S8). In tumor cells
we show that transcriptional responses mediated by STAT3
are involved in the generation of actomyosin contractility. A
key role of the STAT3 transcriptional response is to regulate
the expression of GP130-IL6ST, the common subunit of cytokine
receptors required for JAK activation. Overlaid on JAK-STAT3
signaling is an input from ROCK that regulates the phosphoryla-
tion status of STAT3. Previous studies have shown that Rho
signaling positively influences STAT3 phosphorylation (Aznar
et al., 2001), but it was not known which Rho-dependent
signaling pathway is involved. Thus, JAK signaling activates
ROCK, then ROCK and actomyosin contractility enhance
STAT3 phosphorylation. Therefore, there is positive feedback
from STAT3 to GP130-IL6ST expression and JAK activity, result-
ing in ROCK activation and enhanced STAT3 phosphorylation
(see Figure S7E). Such an organization may provide the basis
for sustained signaling responses required for the process of
invasion that takes place over a prolonged time scale.Figure 7. A Network Centered on STAT3 Regulates Actomyosin Contr
(A) Secreted LIF in A375M2 cells treated with ROCK inhibitors.
(B) Immunoblot for GP130-IL6ST after treatment of A375M2 cells with ROCK inh
(C) Immunoblot for P-MLC after LIF depletion by siRNA.
(D) Quantification of P-MLC levels (n = 4, mean + SE).
(E) Immunoblot for P-MLC after IL-6R or LIFR depletion by siRNA.
(F) Quantification of P-MLC levels (n = 4, mean + SE).
(G) Images of A375M2 depleted of LIF by siRNA. Scale bar represents 50 mm.
(H) Percent (%) rounded and elongated A375M2 cells after depletion of LIF by s
(I) Percent (%) rounded and elongated A375M2 cells after depletion of IL-6R by
(J) Immunoblot for IL-6R.
(K) Images of A375M2 depleted of LIFR by siRNA. Scale bar represents 50 mm.
(L) Percent (%) rounded and elongated A375M2 cells after depletion of LIFR by
In (H), (I), and (L), 600 cells/experiment (n = 3, mean + SE). Student’s t test, **p <STAT3 activation has been reported to be involved in tumor
invasion (Xiong et al., 2008; Yakata et al., 2007; Zhao et al.,
2008) and regulates the expression of matrix metalloproteinases
MMP-1, MMP-2, and MMP9 (Itoh et al., 2006; Song et al., 2008;
Xie et al., 2004) and MUC1 (Gaemers et al., 2001), all of which
have roles in tumor invasion. It is striking that we find that
STAT3 phosphorylation in melanoma cells is associated with
the round morphology consequent on high levels of actomyosin
contractility that is linked to a more aggressive phenotype (Viros
et al., 2008).
High levels of cytokines are found in melanomas, squamous
cell carcinomas, and other tumors (Melnikova and Bar-Eli,
2009; van Kempen et al., 2003). In melanoma, IL-6 has been
shown to be upregulated in disease progression (Moretti et al.,
1999) and may be produced by tumor cells or within the tumor
microenvironment (Melnikova and Bar-Eli, 2009). As well as in
tumor cells, we find P-STAT3 in tumor-associated cells such
as inflammatory cells, fibroblasts, and endothelial cells (Chen
et al., 2008) in human melanomas (Figure S8H).
Our studies reveal roles for cytokine signaling in mediating
cancer cell dissemination both in force-mediated matrix remod-
elling by CAFs and in amoeboid motility of tumor cells. These
results suggest that blocking cytokine-signaling pathways may
impinge on tumor cell invasion as well as proliferation and
survival. Therapeutic agents such as blocking antibodies against
cytokines (Rose-John et al., 2007) or small molecule inhibitors of
JAK kinase (Pedranzini et al., 2006) or STAT activity (Yue and
Turkson, 2009) may be useful agents to block invasion and
metastasis.
EXPERIMENTAL PROCEDURES
Cell Culture
CAFs were cultured from a resection of an oral SCC in 10% FCS and
DMEM (Gaggioli et al., 2007). SCC12 cells were cultured in FAD media. Mela-
noma cells were maintained in DMEM or RPMI containing 10% fetal calf
serum.
Cell Culture on Thick Layers of Collagen and Time-Lapse
Phase-Contrast Microscopy
Fibrillar bovine dermal collagen was prepared at 1.7 mg/ml in DMEM accord-
ing to the manufacturer’s protocol (Cohesion, Palo Alto, CA): 300 ml/well in
24-well plates, 700 ml/well in 12-well plates. Melanoma cells were seeded on
top of collagen in medium containing 10% serum, allowed to adhere for
24 hr, and medium was changed to 1% serum for 16 hr. When calculating
P-MLC levels relative to mock or control, tubulin levels were used for
normalization.actility
ibitors or blebbistatin.
iRNA.
siRNA (600 cells/experiment, n = 3, mean + SE).
siRNAs. LIFR KO is shown by qPCR analysis.
0.01 and *p < 0.05 in (D), (F), (H), (I), and (L). See also Figure S7.
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Figure 8. STAT3 Phosphorylation Correlates with a Contractile Phenotype In Vivo
(A and B) (A) Histogram of roundness versus intensity of P-STAT3 staining in A375M2 subcutaneous tumors. (B) is as (A) for WM1361 tumors (n = 100 cells/tumor;
Kruskal-Wallis, p < 0.0001). P-STAT3 staining in sections from A375M2 or WM1361 tumors is shown.
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Cancer Cell
JAK Signaling to Actomyosin ContractilityCytokine Measurements
LIF levels were measured using BD CBA (Cytometric Bead Array) Functional
Bead system.
Tumor Imaging
Nude mice were injected subcutaneously, and when tumors were 3–7 mm in
diameter, mice were anesthetized and imaged as described (Wyckoff et al.,
2006). All animal experiments were carried out under license from the Home
Office, UK.
Microarray
RNA was extracted from cells seeded on top of collagen using TRIzol (Invitro-
gen, Carlsbad, CA) followed by QIAGEN RNeasy Midi Kit. cRNA was prepared
according to the GeneChip Expression Analysis Technical Manual (Affymetrix),
hybridized onto HU133A chips (Affymetrix), and scanned by a GeneArray 2500
Scanner (Affymetrix). Network and enrichment analysis of the gene lists was
performed using MetaCore from GeneGo Inc. (http://www.genego.com/
metacore.php).
Patient Samples
Hematoxylin and eosin-stained slides assessed belong to the archives of the
Royal Surrey County Hospital UK and Royal Marsden Hospital Foundation
Trust. Slides were coded and uncoupled from personal identifiers. Staining
for P-STAT3 was performed on surplus paraffin-embedded archival material.
All procedures using human tissues were approved by the Ethics Committees
of the Institute of Cancer Research and the Royal Marsden Hospital Founda-
tion Trust and Royal Surrey County Hospital UK in accordance with the Human
Tissue Act 2004.
Statistical Analyses
Student’s t test was performed for quantifications of P-MLC, percent (%)
elongated or rounded-type cells, and invasive index; ** indicates p < 0.01,
and * indicates p < 0.05. Error bars are plus standard error (+SE). For the
in vivo scatter plot in Figure 3I, the Mann-Whitney U test was used.
ACCESSION NUMBERS
Gene microarray data are deposited at the NCBI Gene Expression Omnibus
(http://www.ncbi.nlm.nih.gov/geo) with accession numbers GSM586484–
GSM586501.
SUPPLEMENTAL INFORMATION
Supplemental Information includes eight figures, two tables, threemovies, and
Supplemental Experimental Procedures and can be found with this article on-
line at doi:10.1016/j.ccr.2011.06.018.
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